Newsroom

Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the third quarter ended September 30, 2025, and raised its revenue […]

read more +
Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer

New leadership appointments strengthen Sight Sciences’ commitment to advancing our interventional dry eye initiatives and driving scalable operations and growth MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard […]

read more +
Sight Sciences to Present at Two Upcoming Investor Conferences

MENLO PARK, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced plans to present at the upcoming Stifel 2025 Healthcare Conference and the Piper Sandler […]

read more +
Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025

MENLO PARK, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced it will report financial results for the third quarter ended September 30, 2025, after […]

read more +
Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use

The study, published in The European Journal of Ophthalmology, included 29 publications and concluded that favorable long-term safety and efficacy profiles make OMNI a beneficial treatment option for patients with primary open-angle glaucoma MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology […]

read more +
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

PDF Version MENLO PARK, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference […]

read more +
Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the second quarter ended June 30, 2025, and raised its revenue […]

read more +
Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025

PDF Version MENLO PARK, Calif., July 24, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced it will report financial results for the second quarter ended June 30, 2025, […]

read more +
Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025

MENLO PARK, Calif., April 24, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced it will report financial results for the first quarter ended March 31, 2025, after […]

read more +